.ALPHA.-DIHYDROARTEMISININ

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H24O5
Molecular Weight	284.3481
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](O)[C@@H]2C)O4

InChI

InChIKey=BJDCWCLMFKKGEE-KDTBHNEXSA-N

InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12-,13-,14-,15-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.htmlhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/11231359 | https://www.ncbi.nlm.nih.gov/pubmed/9241384 | https://www.ncbi.nlm.nih.gov/pubmed/1966574
Curator's Comment: Description was created based on several sources, including http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001199/human_med_001450.jsp&mid=WC0b01ac058001d124 | https://www.hpra.ie/docs/default-source/3rd-party-documents/educational-materials/eurartesim_hcp-guide.pdf?sfvrsn=4 | https://www.ncbi.nlm.nih.gov/pubmed/20649950

Sodium artesunate, an artemisinin derivative, is used in malaria treatment. Artesunate, has been licensed in Thailand for the treatment of falciparum malaria since 1990. It is a potent antimalarial drug that can reduce parasitaemia by 90% within 24 h of administration. Sodium artesunate was first isolated in China, it is a water soluble antimalaria used clinically in China.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Pneumocystis carinii 4 Target ID: CHEMBL613064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11802960	Inhibitor 8297
Sodium/potassium-transporting ATPase subunit alpha-1 16 Target ID: P06685 Gene ID: 24211.0 Gene Symbol: Atp1a1 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8732048 \| https://www.ncbi.nlm.nih.gov/pubmed/1966574	Inhibitor 8297
Plasmodium falciparum 74 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1394893	Inhibitor 8297	4.1 nM [IC50]
Plasmodium yoelii 3 Target ID: CHEMBL612889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1307277	Inhibitor 8297
Plasmodium berghei 9 Target ID: CHEMBL612653 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3009719	Inhibitor 8297
Plasmodium falciparum 74 Target ID: CHEMBL364 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf	Inhibitor 8297
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25348537	Binding Agent 1064
DNA 278 Target ID: CHEMBL2366043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25348537	Binding Agent 1064
Plasmodium falciparum 74 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8891104	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Plasmodium falciparum malaria 63 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15828489 https://www.ncbi.nlm.nih.gov/pubmed/9241384	Primary	Approved 8429	Sodium artesunate Approved Use Plasmodium falciparum malaria
Plasmodium falciparum malaria 63 Sources: https://www.hpra.ie/docs/default-source/3rd-party-documents/educational-materials/eurartesim_hcp-guide.pdf?sfvrsn=4	Curative	Approved 8429	Eurartesim Approved Use Eurartesim tablets (piperaquine tetraphosphate in combination with dihydroartemisinin) are indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants aged ≥6 months and weighing ≥5kg. Launch Date 2011
Malaria 95 Sources: https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html	Curative	Approved 8429	Unknown Approved Use Although not FDA-approved for use in the United States, artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinidine.
Schistosoma mansoni infection 8 Sources: https://ClinicalTrials.gov/show/NCT01054651	Curative	Phase III 656	Unknown Approved Use Unknown
Colorectal cancer 101 Sources: https://ClinicalTrials.gov/show/NCT03093129	Primary	Phase II 1132	Unknown Approved Use Unknown
Cervical cancer 40 Sources: https://ClinicalTrials.gov/show/NCT02354534	Primary	Phase I 428	Unknown Approved Use Unknown
Hepatocellular carcinoma 83 Sources: https://ClinicalTrials.gov/show/NCT02304289	Primary	Phase I 428	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://ClinicalTrials.gov/show/NCT00764036	Primary	Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
3.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTENIMOL unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTESUNATE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
3.5 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTENIMOL unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTESUNATE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTENIMOL unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTESUNATE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
7% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTENIMOL unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
7% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	2.4 mg/kg multiple, intravenous dose: 2.4 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ARTESUNATE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.4 mg/kg 1 times / day multiple, intravenous (complex) Recommended Dose: 2.4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 2.4 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	unhealthy, 1-72 years n = 92 Health Status: unhealthy Condition: malaria Age Group: 1-72 years Sex: M+F Population Size: 92 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	Other AEs: Anemia, Transaminases increased... Other AEs: Anemia (65%) Transaminases increased (27%) Thrombocytopenia (18%) Hyperbilirubinemia (14%) Acute renal failure (10%) Leukocytosis (10%) Acute respiratory distress syndrome (8%) Lymphopenia (7%) Neutropenia (5%) Disseminated intravascular coagulation (3%) Creatinine increased (3%) Pneumonia (3%) Pulmonary edema (3%) Diarrhea (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf
100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8205643/	unhealthy, 15-35 years n = 31 Health Status: unhealthy Condition: Uncomplicated Malaria Age Group: 15-35 years Sex: M Population Size: 31 Sources: https://pubmed.ncbi.nlm.nih.gov/8205643/	Other AEs: Nausea, Dizziness... Other AEs: Nausea (grade 1, 45%) Dizziness (grade 1, 52%) Vomiting (grade 1, 26%) Convulsions (grade 1, 3%) Bradycardia (grade 1, 23%) Sources: https://pubmed.ncbi.nlm.nih.gov/8205643/
2.4 mg/kg 1 times / day multiple, intravenous\|oral (complex) Recommended Dose: 2.4 mg/kg, 1 times / day Route: intravenous\|oral Route: multiple Dose: 2.4 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16125588/	unhealthy, 2-87 years n = 730 Health Status: unhealthy Condition: malaria Age Group: 2-87 years Sex: M+F Population Size: 730 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16125588/	Other AEs: Acute renal failure, Hemoglobinuria... Other AEs: Acute renal failure (8.9%) Hemoglobinuria (6.7%) Jaundice (2.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16125588/
25 mg/kg 2 times / 3 weeks multiple, intravenous Highest studied dose Dose: 25 mg/kg, 2 times / 3 weeks Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	unhealthy, 58 years n = 2 Health Status: unhealthy Condition: advanced solid tumor malignancies Age Group: 58 years Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	DLT: Nausea, Vomiting... Dose limiting toxicities: Nausea (grade 3, 1 patient) Vomiting (grade 3, 1 patient) ALT increased (grade 3-4, 1 patient) Neutropenic infection (grade 3-4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29392450
18 mg/kg 2 times / 3 weeks multiple, intravenous MTD Dose: 18 mg/kg, 2 times / 3 weeks Route: intravenous Route: multiple Dose: 18 mg/kg, 2 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	unhealthy, 58 years n = 6 Health Status: unhealthy Condition: advanced solid tumor malignancies Age Group: 58 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	DLT: Hypersensitivity reaction... Dose limiting toxicities: Hypersensitivity reaction (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29392450
12 mg/kg 2 times / 3 weeks multiple, intravenous Studied dose Dose: 12 mg/kg, 2 times / 3 weeks Route: intravenous Route: multiple Dose: 12 mg/kg, 2 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	unhealthy, 58 years n = 6 Health Status: unhealthy Condition: advanced solid tumor malignancies Age Group: 58 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29392450	DLT: Neutropenic fever... Dose limiting toxicities: Neutropenic fever (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29392450

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 810 CYP2C19 1478 CYP3A4/5 278 CYP1A2 1524	UGT1A9 380 UGT2B7 389 P-gp 1537	CYP2A6 79 CYP3A 129

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]	DHA 3
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]	DHA 3
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]	DHA 3
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	no [IC50 >100 uM]	DHA 3
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	weak [IC50 32.3 uM]	DHA 3
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=241 Page: 241.0	weak [IC50 75.4 uM]	DHA 3
CYP2A6 739	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=258 Page: 258.0	yes	DHA 3
CYP3A 298	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=258 Page: 258.0	yes	DHA 3

Drug as victim

Target	Modality	Activity	Metabolite
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=242 Page: 242.0	no	DHA 3
UGT1A9 380	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=85 Page: 85.0	yes	DHA 3
UGT2B7 389	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=85 Page: 85.0	yes	DHA 3

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf#page=38 Page: 38.0		DHA 3

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63918	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63918
MolPort	MolPort-006-392-384	https://www.molport.com/shop/molecule-link/MolPort-006-392-384
ZINC	ZINC000014096305	http://zinc15.docking.org/substances/ZINC000014096305
eMolecules	1935656	https://www.emolecules.com/cgi-bin/more?vid=1935656
eMolecules	29933844	https://www.emolecules.com/cgi-bin/more?vid=29933844
eMolecules	31224737	https://www.emolecules.com/cgi-bin/more?vid=31224737

PubMed

Title	Date	PubMed
Antimalarial agents, 2. Artesunate, an inhibitor of cytochrome oxidase activity in Plasmodium berghei.	1986 Jan-Feb	3009719
[Effects of sodium artesunate on electrical properties and Na+,K(+)-ATPase activities of mouse small intestine].	1990 Jul	1966574
Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens.	1997 Sep 30	9241384
Effects of sodium artesunate, a new antimalarial drug, on renal function.	2001 Mar	11231359
Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand.	2002 Nov	12479545
Diuretic effect of sodium artesunate in patients with malaria.	2002 Nov	12479546
Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.	2003 Jan	12499215
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.	2003 Sep	12920490
Randomized control trial of quinine and artesunate in complicated malaria.	2004 Apr	15107507
Artesunate in the treatment of metastatic uveal melanoma--first experiences.	2005 Dec	16273263
Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.	2005 Feb-Apr	15878303
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.	2005 Jan-Feb	15796179
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.	2007 Dec 21	18154655
Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.	2008 Nov 6	18986553
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.	2009 Jul	19513562
The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.	2009 Sep 2	19725966
Factors determining sensitivity or resistance of tumor cell lines towards artesunate.	2010 Apr 15	20144594
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.	2010 May	20194698
Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.	2010 Oct 21	20964849
Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells.	2014 Aug 5	24704559
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.	2014 Jan 20	24443033
Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.	2014 Oct	25071004
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.	2015 Jun	25752796
Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells.	2015 Oct 19	26340163

Patents

Sample Use Guides

In Vivo Use Guide

Artesunate can be used orally, by intravenous or intramuscular injection or as a suppository. As an injection, artesunate 2.4mg/kg bw i.v or i.m. given on admission (time =0), then at 12hr and 24hr, then once a day.

Route of Administration: Other

In Vitro Use Guide

An artemisinin concentration of 100-300 nM in vitro caused swelling of the endoplasmic reticulum and mitochondria, as well as injuries both to the limiting and to the nuclear membranes of chloroquine-resistant P. falciparum (ItG2 strain) within 2 h.

Name

Type

Language

.ALPHA.-DIHYDROARTEMISININ

Common Name

English

DIHYDROARTIMISININ

Common Name

English

3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL, DECAHYDRO-3,6,9-TRIMETHYL-, (3R,5AS,6R,8AS,9R,10R,12R,12AR)-

Common Name

English

3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL, DECAHYDRO-3,6,9-TRIMETHYL-, (3R-(3.ALPHA.,5A.BETA.,6.BETA.,8A.BETA.,9.ALPHA.,10.BETA.,12.BETA.,12AR*))-

Common Name

English

NSC-758682

Code

English

Code System Code Type Description

CAS

81496-81-3